Yi Nam-Joon, Suh Kyung-Suk, Lee Hae Won, Shin Woo Young, Kim Juhyun, Kim Won, Kim Yoon Jun, Yoon Jung-Hwan, Lee Hyo-Suk, Lee Kuhn Uk
Department of Surgery, Seoul National University College of Medicine, Seoul, Korea.
Liver Transpl. 2009 May;15(5):496-503. doi: 10.1002/lt.21606.
Although adult-to-adult living donor liver transplantation (ALDLT) has shown comparable outcomes to deceased donor liver transplantation, the outcome of patients with a high MELD score (>25) and a small-for-size graft (SFSG<0.8% of graft-to-recipient weight ratio) is not known. For 7 years, 167 consecutive hepatitis B virus-infected recipients underwent ALDLT at our institution. Based on their MELD score without additional score for hepatocellular carcinoma (HCC), the recipients were divided into Group L (low MELD score, n = 105) or Group H (high MELD score, n = 62). To analyze the risk of the graft size, the patients were further stratified as follows: Group Hs (high MELD score and SFSG, n = 11), Hn (high MELD score and normal size graft, n = 51), Ls (low MELD score and SFSG, n = 18), and Ln (low MELD score and normal size graft, n = 87). The primary endpoint was one-year patient survival rate (1-YSR). The mean follow-up period was 32.6 months. The mean MELD scores were 17.1 in Group L and 32.6 in Group H. Group H had more patients with the complications of cirrhosis but less patients with HCC than Group L (p < 0.05). However, major morbidity rates and 1-YSR were similar in comparisons between Group L (46.7% and 86.7%) and H (59.7% and 83.8%) (p > 0.05). 1-YSR was similar among Group Hs (72.7%), Hn (86.3%), Ls (83.3%), and Ln (88.5%) groups (p = 0.278). The multivariate analysis revealed accompanying HCC and the year of transplant were risk factors for poor 1-YSR. However, 1-YSR without HCC patients was also similar in comparisons between group L (90.2%) and H (91.7%) (p = 0.847), and among Group Hs (80.0%), Hn (94.7%), Ls (72.7%), and Ln (96.7%) (p = 0.072). In conclusion, high MELD score (>25) didn't predict 1-YSR in ALDLT. Improvement of the 1-YSR might be affected by center's experience as well as the selection of patients with low risk of recurrence of HCC.
尽管成人活体肝移植(ALDLT)的效果已显示与尸体供肝移植相当,但对于终末期肝病模型(MELD)评分高(>25)且移植肝体积过小(SFSG<移植肝与受者体重比的0.8%)的患者,其预后尚不清楚。7年间,我院连续167例乙型肝炎病毒感染受者接受了ALDLT。根据其MELD评分(未额外计入肝细胞癌(HCC)评分),将受者分为L组(低MELD评分,n = 105)或H组(高MELD评分,n = 62)。为分析移植肝大小的风险,患者进一步分层如下:Hs组(高MELD评分且移植肝体积过小,n = 11)、Hn组(高MELD评分且移植肝体积正常,n = 51)、Ls组(低MELD评分且移植肝体积过小,n = 18)和Ln组(低MELD评分且移植肝体积正常,n = 87)。主要终点为1年患者生存率(1 - YSR)。平均随访期为32.6个月。L组的平均MELD评分为17.1,H组为32.6。与L组相比,H组肝硬化并发症患者更多,但HCC患者更少(p < 0.05)。然而,L组(46.7%和86.7%)与H组(59.7%和83.8%)比较时,主要发病率和1 - YSR相似(p > 0.05)。Hs组(72.7%)、Hn组(86.3%)、Ls组(83.3%)和Ln组(88.5%)的1 - YSR相似(p = 0.278)。多因素分析显示,合并HCC和移植年份是1 - YSR不良的危险因素。然而,无HCC患者的1 - YSR在L组(90.2%)和H组(91.7%)比较时也相似(p = 0.847),在Hs组(80.0%)、Hn组(94.7%)、Ls组(72.7%)和Ln组(96.7%)中也相似(p = 0.072)。总之,高MELD评分(>25)在ALDLT中并不能预测1 - YSR。1 - YSR的改善可能受中心经验以及HCC复发低风险患者的选择影响。